Skip to main content
SpringerLink
Log in

Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn’s Disease: A Meta-Analysis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Recent studies suggested that anti-Saccharomyces cerevisiae antibody (ASCA) status was associated with diagnostic findings, stratified classification phenotypes, disease activity and clinical course of Crohn’s disease (CD). However, the relationship between ASCA status and phenotypes of CD remains controversial in these studies.

Aims

The purpose of this study was to evaluate whether ASCA status is associated with the phenotypes and the risk of surgery in diverse populations in CD.

Methods

We conducted a meta-analysis of studies assessing the association of ASCA status with phenotypes and risk of surgery in CD. Three independent reviewers undertook data extraction. We pooled odds ratios separately for the cohort and case–control studies.

Results

We identified ten cohort studies (n = 2,365) and 14 case–control studies (n = 1,887) that investigated the association of ASCA status with phenotypes and risk of surgery in CD. The meta-analysis of the cohort studies showed significant association between the ASCA-positive status and higher risk of early-onset age (OR 2.25, 95 % CI 1.41–3.57, P < 0.001), ileal involvement disease (1.70, 1.05–2.77, P = 0.03), complicated disease behavior (2.09, 1.71–2.57, P < 0.001), perianal disease (1.49, 1.14–1.94, P = 0.004), and risk for surgery (1.61, 1.29–2.01, P < 0.001). Meta-analysis of the case–control studies also showed a significantly higher risk in ileal involvement disease (1.77, 1.25–2.49, P = 0.001), complicated disease behavior (2.13, 1.70–2.68, P < 0.001), perianal disease (1.96, 1.38–2.78, P < 0.001), and risk for surgery (1.71, 1.17–2.49, P = 0.005), except for the early-onset age (1.16, 0.80–1.69, P = 0.44).

Conclusions

This meta-analysis indicated that positive ASCA status is a risk factor for early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Friedman S, Blumberg RS. Inflammatory bowel disease. In: Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison’s Principles of Internal Medicine, 16th ed. Seoul: McGraw-Hill; 2005:1776–1789.

    Google Scholar 

  2. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. Br Med J. 1988;297:1105–1106.

    Article  CAS  Google Scholar 

  3. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol. 1996;3:219–226.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut. 2000;47:487–496.

    Article  CAS  PubMed  Google Scholar 

  5. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8–15.

    Article  CAS  PubMed  Google Scholar 

  6. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–829.

    Article  CAS  PubMed  Google Scholar 

  7. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490–496.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–1122.

    Article  CAS  PubMed  Google Scholar 

  9. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376–2384.

    Article  PubMed  Google Scholar 

  10. Kim BC, Park S, Han J, et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn’s disease and its relationship to the disease clinical course. Dig Liver Dis. 2007;39:610–616.

    Article  CAS  PubMed  Google Scholar 

  11. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237–1243.

    Article  CAS  PubMed  Google Scholar 

  12. Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Appl Immunol Rev. 2001;2:45–63.

    Article  Google Scholar 

  13. Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38:121–126.

    Article  PubMed  Google Scholar 

  14. Suzuki H, Fukuda Y, Koizuka H, et al. Dietary antigens in Crohn’s disease: antibodies to porcine pancreatic amylase. Am J Gastroenterol. 2008;103:656–664.

    Article  CAS  PubMed  Google Scholar 

  15. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group. Croat Med J. 2003;44:635–638.

    PubMed  Google Scholar 

  16. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.

    Article  CAS  PubMed  Google Scholar 

  18. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.

    Article  CAS  PubMed  Google Scholar 

  19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.

    Article  CAS  PubMed  Google Scholar 

  20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.

    Article  PubMed  Google Scholar 

  21. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207–216.

    Article  CAS  PubMed  Google Scholar 

  22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.

    Article  CAS  PubMed  Google Scholar 

  23. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449–454.

    CAS  PubMed  Google Scholar 

  24. Bernstein CN, Orr K, Blanchard JF, et al. Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn’s disease. Can J Gastroenterol. 2001;15:499–504.

    CAS  PubMed  Google Scholar 

  25. Sostegni R, Daperno M, Ercole E, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis. 2001;33:755–761.

    Article  CAS  PubMed  Google Scholar 

  26. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn’s disease. Inflamm Bowel Dis. 2004;10:521–528.

    Article  PubMed  Google Scholar 

  27. Linskens RK, Mallant-Hent RC, Murillo LS, et al. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn’s disease population. Dig Liver Dis. 2004;36:29–34.

    Article  CAS  PubMed  Google Scholar 

  28. Annese V, Piepoli A, Perri F, et al. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol Ther. 2004;20:1143–1152.

    Article  CAS  PubMed  Google Scholar 

  29. Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn’s disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19:717–721.

    PubMed  Google Scholar 

  30. Preda CM, Diculescu M, Mirea V, et al. Significance of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom J Gastroenterol. 2005;14:23–26.

    PubMed  Google Scholar 

  31. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101:645–652.

    Article  PubMed  Google Scholar 

  32. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–367.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn’s disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis. 2007;13:984–992.

    Article  PubMed  Google Scholar 

  34. Desplat-Jégo S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13:2312–2318.

    PubMed  Google Scholar 

  35. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn’s disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis. 2007;13:143–151.

    Article  PubMed  Google Scholar 

  36. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Clin Gastroenterol Hepatol. 2008;6:1105–1111.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358–1367.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406–414.

    Article  PubMed  Google Scholar 

  39. Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009;48:161–167.

    Article  CAS  PubMed  Google Scholar 

  40. Dassopoulos T, Nguyen GC, Talor MV, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn’s disease in African Americans. Am J Gastroenterol. 2010;105:378–386.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 2010;411:1461–1465.

    Article  CAS  PubMed  Google Scholar 

  42. Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives. World J Gastroenterol. 2010;16:5732–5738.

    Article  PubMed  Google Scholar 

  43. Van Assche G, Rutgeerts P. Medical management of postoperative recurrence in Crohn’s disease. Gastroenterol Clin North Am. 2004;33:347–360.

    Article  PubMed  Google Scholar 

  44. Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2003;17:63–73.

    Article  CAS  PubMed  Google Scholar 

  45. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130:1764–1775.

    Article  CAS  PubMed  Google Scholar 

  46. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn’s disease. Gastroenterology. 2004;127:1076–1084.

    Article  CAS  PubMed  Google Scholar 

  47. Török HP, Glas J, Hollay HC, et al. Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion. 2005;72:119–123.

    Article  PubMed  Google Scholar 

  48. Glas J, Török HP, Vilsmaier F, et al. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion. 2002;66:173–177.

    Article  CAS  PubMed  Google Scholar 

  49. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665–681.

    Article  CAS  PubMed  Google Scholar 

  50. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping for susceptibility locus for Crohn’s disease on chromosome 16. Nature. 1996;379:821–823.

    Article  CAS  PubMed  Google Scholar 

  51. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn’s disease patients. Clin Exp Immunol. 2005;140:354–359.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126:414–424.

    Article  CAS  PubMed  Google Scholar 

  53. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688.

    Article  CAS  PubMed  Google Scholar 

  54. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536–1542.

    Article  CAS  PubMed  Google Scholar 

  55. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102–6108.

    PubMed  Google Scholar 

  56. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response o microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology. 2007;132:576–586.

    Article  CAS  PubMed  Google Scholar 

  57. Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Marla C. Dubinsky (Departments of Pediatrics, Cedars Sinai Medical Center, Los Angeles) for providing the detail data of their study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Guangdong Province Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

    Zhaoxia Zhang, Chen Li, Xinmei Zhao, Chaolan Lv, Qiong He, Shan Lei, Yandong Guo & Fachao Zhi

Authors
  1. Zhaoxia Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinmei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chaolan Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qiong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shan Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yandong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fachao Zhi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fachao Zhi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Z., Li, C., Zhao, X. et al. Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn’s Disease: A Meta-Analysis. Dig Dis Sci 57, 2944–2954 (2012). https://doi.org/10.1007/s10620-012-2244-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2244-y

Keywords

Search

Navigation